استعرض مصدر DuoCover 75 mg

تعليق: نموذج لمشاكل تداخل البلافكس مع الأوميبراز.--احمد شوقي محمدين 18:22، 22 أكتوبر 2016 (ت ع م)


Other concomitant therapy with clopidogrel: Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of medicinal products that inhibit the activity of this enzyme would be expected to result in reduced drug levels of the active metabolite of clopidogrel. The clinical relevance of this interaction is uncertain. As a precaution concomitant use of strong or moderate CYP2C19
inhibitors should be discouraged (see sections 4.4 and 5.2).

'''Medicinal products that inhibit CYP2C19 include omeprazole and esomeprazole'''

==Proton Pump Inhibitors (PPI)==
Omeprazole 80 mg once daily administered either at the same time as clopidogrel or with 12 hours between the administrations of the two drugs decreased the exposure of the active metabolite by 45% (loading dose) and 40% (maintenance dose). The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation. Esomeprazole is expected to give a similar interaction with clopidogrel.

Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies. As a precaution, '''concomitant use of omeprazole or esomeprazole should be discouraged (see section''' 4.4).

Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole. 

The plasma concentrations of the active metabolite was 20% reduced (loading dose) and 14% reduced
(maintenance dose) '''during concomitant treatment with pantoprazole 80 mg''' once daily. This was
associated with a reduction of the mean inhibition of platelet aggregation by 15% and 11%,
respectively. These results indicate that '''clopidogrel can be administered with pantoprazole'''.
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers
(except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of
clopidogrel.\

Other medicinal products: A number of other clinical studies have been conducted with clopidogrel
and other concomitant medicinal products to investigate the potential for pharmacodynamic and
pharmacokinetic (PK) interactions. No clinically significant pharmacodynamic interactions were
observed when clopidogrel was co-administered with atenolol, nifedipine, or both atenolol and
nifedipine. Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced
by the co-administration of phenobarbital or oestrogen. 


http://pure.au.dk/portal/files/73626095/Appendices_A_V.pdf

[[تصنيف:Proton pump inhibitors and vision]]